The Indian Pharmaceutical Market (IPM) has entered a definitive “Gold Rush” phase. The launch of Semaglutide branded generics in late March 2026 has served as a primary catalyst for a historic shift in metabolic health therapy. While the broader market maintains a healthy 10.1% monthly value growth (reaching ₹20,012 Cr), the real story lies in…
Free Membership Required
You must be a Free member to access this content.
Already a member? Log in here
